Severe Asthma Market Size in 7MM was USD 6,076 Million in 2021 | Companies- Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline (GSK), Novartis, Sanofi, Regeneron Pharmaceutical, Avillion, and Others

DelveInsight, a leading market research and consulting firm, has released a comprehensive market report on the Severe Asthma Market, providing valuable insights into the current scenario and future trends of this rapidly evolving market.

The Severe Asthma market report provides current treatment practices, Severe Asthma emerging drugs, market share of individual therapies, and current and forecasted 7MM Severe Asthma market size from 2019 to 2032. The Report also covers current Severe Asthma treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Discover more about therapies set to grab major Severe Asthma Market Share @ Severe Asthma Market Size- https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Severe Asthma Market Report
• Total diagnosed prevalent cases of asthma in the 7MM were found to be approximately 42,612,876 cases in adults and 11,602,740 cases in the pediatric population in the year 2021. These cases are expected to rise significantly by 2032.
• In 2021, the total reported diagnosed prevalent cases (adult+pediatric) of asthma in EU-5 countries were 21,034,152 cases which are expected to rise significantly by 2032.
• The leading Severe Asthma Companies include Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline GSK), Novartis, Sanofi, Regeneron Pharmaceutical, Avillion, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion, and others
• Promising Severe Asthma Pipeline Therapies include Tezepelumab, Escitalopram, Dupilumab, Benralizumab, Seasonal influenza virus vaccine, FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA, Mepolizumab 100 milligrams, Salbutamol, and others
• GSK3511294 (depemokimab), which GSK is developing to treat severe eosinophilic asthma, is a humanized anti-interleukin (IL)-5 monoclonal antibody. As a new biological entity, it is engineered to ensure high affinity and long-acting suppression of IL-5 functions. With an extended half-life and improved IL-5 affinity compared to other approved therapies and is the first biologic to be administered subcutaneously once every 26 weeks. GSK is conducting multiple Phase III trials to assess the safety and efficacy of depemokimab for the treatment of severe eosinophilic asthma.
• PT027, which AstraZeneca is developing in partnership with Avillion, is a fixed-dose combination of albuterol and budesonide. Albuterol, also known as salbutamol, is a shortacting beta2-agonist (SABA), while budesonide is an inhaled corticosteroid (ICS). It is being developed as a pressurized metered-dose inhaler (pMDI) using AstraZeneca's Aerosphere delivery technology. Phase III trials for PT027 are completed, and based on these results, the company plans to file for regulatory submission in the US in 2022
• PT010 being developed by AstraZeneca, is a fixed-dose combination of micronized budesonide, an inhaled corticosteroid (ICS), micronized glycopyrrolate (an anticholinergic), and micronized formoterol fumarate, an inhaled long-acting beta2-adrenergic agonist (a LABA), for oral inhalation administered via a pressurized metered-dose inhaler (pMDI) using Aerosphere delivery technology. Currently, AstraZeneca is conducting multiple phase III trials to assess the safety and efficacy of PT010 in adults and adolescents with severe asthma inadequately controlled with the standard of care. The combination is already approved for the treatment of COPD and marketed as Breztri Aerosphere.
• MRx-4DP0004, which 4D Pharma plc is developing, is a human infant microbiota-derived single bacterial strain, Bifidobacterium breve. In severe asthma, it can concurrently reduce both neutrophilic and eosinophilic infiltration and inflammation in lung bronchoalveolar lavage fluid. It is an oral, immunomodulatory, single-strain live biotherapeutic product (LBP) that increases lung CD4+CD44+ cells and CD4+FoxP3+ cells and decreases activated CD11b+ dendritic cells. 4D Pharma has completed Phase I/IIa trials, and Phase I/IIb trials are ongoing.
• CSJ117 (Ecleralimab), which Novartis is developing, is a potent neutralizing antibody fragment directed against human thymic stromal lymphopoietin (TSLP), an epithelial cellderived cytokine that has an important role in asthmatic airway inflammation. It is formulated as an engineered powder in hard capsules, PulmoSol, for delivery to the lungs via a dry powder inhaler. Currently, Novartis is conducting Phase II trials for CSJ117 to assess its safety and efficacy at different doses and plans to file for approval by 2026.

To explore more information on the latest breakthroughs in the Severe Asthma treatment landscape of the report, click here @ Severe Asthma Market Outlook- https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Asthma Overview
Asthma is the most common chronic respiratory illness worldwide. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodeling that results in airway hyper-responsiveness (AHR), leading to variable and excessive airway narrowing.

Severe Asthma Epidemiology Segmentation in the 7MM
• Diagnosed prevalent cases
• Severe Asthma Severity-specific diagnosed prevalent cases
• Severe Asthma Type-specific diagnosed prevalent cases

Download the report to understand which factors are driving Severe Asthma Epidemiology Trends @ Severe Asthma Epidemiological Insights- https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Asthma Treatment Market
Most asthma control medications focus on reducing airway inflammation and preventing the associated symptoms. The mainstay treatment for persistent asthma consists of inhaled corticosteroids. Quick-relief (reliever) or rescue medicines quickly ease symptoms that arise acutely Short-acting beta-agonists (SABAs) rapidly reduce airway bronchoconstriction and are recommended rescue medication for rapid symptom relief. Additional long-term controller medicines, such as long-acting beta 2 agonists (LABA), montelukast, or theophylline, are added if asthma is still uncontrolled. Oral corticosteroids can be added to treatment if patients are still experiencing symptoms and flare-ups. There are currently six approved monoclonal antibodies for add-on biological treatment of severe asthma. They include omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab for the treatment of severe asthma. At present, there is no approved therapy for severe non-eosinophilic asthma which is non-responsive to corticosteroid treatment also.

Severe Asthma Market Size
Severe Asthma market size in seven major markets was approximately USD 6,076 million in 2021, which is further expected to increase by 2032. Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Severe Asthma. Upcoming therapies such GSK3511294 (Depemokimab) and PT027 have the potential to create a significant positive shift in the Severe Asthma market size.

Severe Asthma Marketed Drugs
Cinqair (reslizumab): Teva Pharmaceutical
Cinqair injection is a humanized interleukin-5 antagonist monoclonal antibody for add-on maintenance treatment of adult patients with severe asthma and with an eosinophilic phenotype, developed by Teva Pharmaceuticals. Cinqair is for intravenous infusion only. It is not to be administered as an intravenous push or bolus. The recommended dosage regimen is 3 mg/kg once every 4 weeks administered by intravenous infusion over 20-50 min.
Fasenra (benralizumab): AstraZeneca
Fasenra (benralizumab) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution for subcutaneous injection. Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM, developed by AstraZeneca. The IL-5 receptor is expressed on the surface of eosinophils and basophils. Benralizumab is produced in Chinese hamster ovry cells by recombinant DNA technology.

Severe Asthma Emerging Drugs
GSK3511294 (Depemokimab): GlaxoSmithKline
GSK3511294 (depemokimab), which GlaxoSmithKline is developing to treat severe eosinophilic asthma, is a humanized anti-interleukin (IL)-5 monoclonal antibody. As a new biological entity, it is engineered to ensure high affinity and long-acting suppression of IL-5 functions. IL-5 are cytokines responsible for the proliferation, activation, and survival of eosinophils, thus making them a proven treatment target for severe asthma patients with higher levels of eosinophils.Depemokimab with an extended half-life and improved IL-5 affinity compared to other approved therapies is the first biologic to be administered subcutaneously once every 26 weeks. Currently, GlaxoSmithKline is conducting multiple Phase III trials to assess the safety and efficacy of depemokimab for the treatment of severe eosinophilic asthma.
PT027: AstraZeneca/Avillion
PT027, which AstraZeneca is developing in partnership with Avillion, is a fixed-dose combination of albuterol and budesonide. Albuterol, also known as salbutamol, is a short-acting beta2-agonist (SABA), while budesonide is an inhaled corticosteroid (ICS). It is a SABA/ICS fixed-dose rescue therapy for moderate to severe asthma being developed as a pressurized metered-dose inhaler (pMDI) using AstraZeneca's Aerosphere delivery technology. AstraZeneca has completed Phase III trials for PT027 and based on these results, the company plans to file for regulatory submission in the US in 2022

To know more about Severe Asthma Therapies options, visit @ Severe Asthma Therapeutics Market- https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Severe Asthma Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Companies- Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline GSK), Novartis, Sanofi, Regeneron Pharmaceutical, Avillion, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion, and others
• Severe Asthma Pipeline Therapies include Tezepelumab, Escitalopram, Dupilumab, Benralizumab, Seasonal influenza virus vaccine, FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA, Mepolizumab 100 milligrams, Salbutamol, and others.
• Severe Asthma Market Dynamics: Severe Asthma Market Drivers and Barriers

Discover more about Severe Asthma Drugs in development @ Severe Asthma Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Severe Asthma Market Overview at a Glance
4. Severe Asthma Market: Future Perspective
5. Executive Summary of Severe Asthma
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Drugs
12. Severe Asthma: Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. Severe Asthma Market Drivers
15. Severe Asthma Market Barriers
16. Severe Asthma SWOT Analysis
17. Severe Asthma Unmet Needs
18. Reimbursement and Market Access
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.